Until the diagnosis is confirmed by the detection of BCR::ABL1 and the definition of the immunophenotype (lymphoid vs. myeloid), supportive therapy is administered as in acute leukemia (prevention of tumor lysis syndrome according to institutional standards). This evidence concerns the gene ABL1 and Tumor Lysis Syndrome.